CN115667291B - 一种白细胞介素29突变体蛋白 - Google Patents

一种白细胞介素29突变体蛋白

Info

Publication number
CN115667291B
CN115667291B CN202180037021.9A CN202180037021A CN115667291B CN 115667291 B CN115667291 B CN 115667291B CN 202180037021 A CN202180037021 A CN 202180037021A CN 115667291 B CN115667291 B CN 115667291B
Authority
CN
China
Prior art keywords
mutant
protein
seq
interleukin
mutant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180037021.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115667291A (zh
Inventor
杨柳
李岩
冯静
郭万军
潘海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Xianweida Biotechnology Co ltd
Sciwind Biosciences Co Ltd
Original Assignee
Hangzhou Xianweida Biotechnology Co ltd
Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Xianweida Biotechnology Co ltd, Sciwind Biosciences Co Ltd filed Critical Hangzhou Xianweida Biotechnology Co ltd
Publication of CN115667291A publication Critical patent/CN115667291A/zh
Application granted granted Critical
Publication of CN115667291B publication Critical patent/CN115667291B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202180037021.9A 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白 Active CN115667291B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020092613 2020-05-27
CNPCT/CN2020/092613 2020-05-27
PCT/CN2021/075907 WO2021238302A1 (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Publications (2)

Publication Number Publication Date
CN115667291A CN115667291A (zh) 2023-01-31
CN115667291B true CN115667291B (zh) 2025-08-05

Family

ID=78745522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037021.9A Active CN115667291B (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Country Status (6)

Country Link
US (1) US12703728B2 (enExample)
EP (1) EP4159748A4 (enExample)
JP (1) JP7741108B2 (enExample)
CN (1) CN115667291B (enExample)
AU (1) AU2021280623B9 (enExample)
WO (1) WO2021238302A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
CN107698682A (zh) * 2010-05-03 2018-02-16 百时美施贵宝公司 血清白蛋白结合分子
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031316A (zh) 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
US7351689B2 (en) 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
JP2009502803A (ja) 2005-07-20 2009-01-29 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
CN103224951A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第35位精氨酸定点突变为赖氨酸的变异体及其制备方法
CN103224952A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第33位赖氨酸、35位精氨酸定点突变为精氨酸、赖氨酸的变异体及其制备方法
CN103923209B (zh) 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085657A (zh) 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种干扰素突变体及聚乙二醇衍生物
CN104402988A (zh) 2014-12-12 2015-03-11 江南大学 一种人白细胞介素-29的重组变异体及其制备方法
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698682A (zh) * 2010-05-03 2018-02-16 百时美施贵宝公司 血清白蛋白结合分子
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物

Also Published As

Publication number Publication date
JP2023527048A (ja) 2023-06-26
EP4159748A4 (en) 2024-02-21
AU2021280623A1 (en) 2023-02-02
EP4159748A1 (en) 2023-04-05
US20230265144A1 (en) 2023-08-24
WO2021238302A1 (zh) 2021-12-02
AU2021280623B9 (en) 2024-03-14
US12703728B2 (en) 2026-08-11
CN115667291A (zh) 2023-01-31
JP7741108B2 (ja) 2025-09-17
AU2021280623B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
CN113498417B (zh) 多肽、其制备方法和用途
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
CN106232616B (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2012162567A (ja) 変えられた空間構造を備えるインターフェロン及びその応用
CN113292638A (zh) 用于抗冠状病毒感染的多肽药物及其方法和应用
CN113150107B (zh) 一种白细胞介素29突变体蛋白
CN112870336B (zh) 一种白细胞介素29突变体蛋白制剂
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
JP7741108B2 (ja) インターロイキン２９変異体タンパク質
CN115772227A (zh) 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
CN115385998B (zh) 稳定的iii型干扰素蛋白及其融合蛋白
US20230374091A1 (en) Annexin a5 compositions and methods
CN111825773B (zh) 重组人TSG6-IFNα融合蛋白及其制备方法以及其作为抗病毒药物的应用
EP4386008A1 (en) New mutant of recombinant ganoderma lucidum immunoregulatory protein and application thereof
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
CN113121668B (zh) PEG修饰的可抑制gp96的多肽、其制备方法及用途
WO2010043046A1 (en) Peptide inhibitors of type iii secretion
US9359421B2 (en) Suppressor of the endogenous interferon-gamma
US20220119464A1 (en) Protein inhibitors with reduced immunogenicity and resistance to degradation, and methods for their preparation and use
CA2256368A1 (en) An interleukin-5 antagonist
HK40083738A (en) Soluble ace2 and fusion protein, and applications thereof
WO2022066798A1 (en) Interferon tau fc-fusion proteins and methods for treating coronavirus infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 310018 Room 1802, Building 2, Hangzhou East International Business Center, Qiantang District, Hangzhou City, Zhejiang Province

Applicant after: Hangzhou Xianweida Biotechnology Co.,Ltd.

Address before: Room 815-818, building 17, No.57, kejiyuan Road, Baiyang street, Hangzhou Economic and Technological Development Zone, Hangzhou City, Zhejiang Province 310018

Applicant before: HANGZHOU SCIWIND BIOSCIENCES Co.,Ltd.

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20230131

Assignee: Zhengda Pharmaceutical (Guangzhou) Co.,Ltd.

Assignor: Hangzhou Xianweida Biotechnology Co.,Ltd.

Contract record no.: X2024980010844

Denomination of invention: A mutant protein of interleukin 29

License type: Exclusive License

Record date: 20240730

GR01 Patent grant
GR01 Patent grant